CVRX's three largest insider shareholders as of June 18, 2026 are Johnson Johnson (TenPercentOwner, 4.04Mn shares), Partners 10 L P Nea (TenPercentOwner, 2.20Mn shares), Enterprise Associates 10 L P New (TenPercentOwner, 2.03Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Johnson Johnson | - | 0 | 4,040,861 | 01 Dec, 2025 |
| John M Nehra | - | 28,266 | 100 | 02 Jul, 2021 |
| Plc Glaxosmithkline | - | 0 | 1,007,583 | 06 Jul, 2021 |
| Enterprise Associates 10 L P New | - | 2,026,083 | 0 | 07 Jul, 2021 |
| Partners 10 L P Nea | - | 0 | 2,199,471 | 07 Jul, 2021 |
| Joseph P Slattery | - | 30,645 | 0 | 15 Aug, 2024 |
| Gregory Morrison | Chief Human Resources Officer | 34,000 | 0 | 04 Mar, 2026 |
| Kevin Hykes | Pres Ceo | 284,237 | 0 | 03 Mar, 2026 |
| Kirk G. Nielsen | - | 0 | 1,910,134 | 19 May, 2025 |
| Nadim Yared | Chief Executive Officer | 26,255 | 0 | 31 Jan, 2024 |
| Mudit K. Jain | - | 0 | 980,183 | 23 Feb, 2026 |
| Ali Behbahani | - | 316 | 0 | 18 Dec, 2023 |
| Brent Binkowski | Chief Operating Officer | 31,600 | 0 | 03 Mar, 2026 |
| Geoffrey B Pardo | - | 0 | 1,829,022 | 02 Jul, 2021 |
| Liz Galle | Vp Of Global Clinical Research | 778 | 0 | 18 Oct, 2023 |
| Dean Bruhn-Ding | Vp Of Reg. Affairs And Qa | 54,648 | 0 | 10 Feb, 2022 |
| John Brintnall | Chief Strategy Officer And Sec | 21,901 | 0 | 26 Apr, 2022 |
| Jared Oasheim | Chief Financial Officer | 96,703 | 0 | 03 Mar, 2026 |
| Paul Verrastro | Chief Mktg Strat Officer | 60,551 | 0 | 03 Mar, 2026 |
| Craig E. Palmer | Svp, U.S. Sales | 1,229 | 0 | 27 Mar, 2024 |
| Robert Allen John | Chief Revenue Officer | 86,036 | 0 | 03 Mar, 2026 |
| Philip B. Adamson | Chief Medical Officer | 61,578 | 0 | 16 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 27 Feb, 2026 | Philip B. Adamson | Common Stock | A | 41,000 | $0.00 | 62,840 | D | A |
| 02 Mar, 2026 | Philip B. Adamson | Common Stock | D | 1,262 | $7.90 | 61,578 | D | S |
| 27 Feb, 2026 | Philip B. Adamson | Stock Option (right to buy) | A | 62,000 | $0.00 | 62,000 | D | A |
| 02 Mar, 2026 | Gregory Morrison | Common Stock | A | 34,000 | $0.00 | 34,000 | D | A |
| 02 Mar, 2026 | Gregory Morrison | Stock Option (right to buy) | A | 154,500 | $0.00 | 154,500 | D | A |
| 27 Feb, 2026 | Kevin Hykes | Common Stock | A | 159,000 | $0.00 | 292,000 | D | A |
| 27 Feb, 2026 | Robert Allen John | Common Stock | A | 35,000 | $0.00 | 90,000 | D | A |
| 27 Feb, 2026 | Paul Verrastro | Common Stock | A | 45,000 | $0.00 | 61,835 | D | A |
| 27 Feb, 2026 | Kevin Hykes | Common Stock | A | 159,000 | $0.00 | 292,000 | D | A |
| 27 Feb, 2026 | Robert Allen John | Common Stock | A | 35,000 | $0.00 | 90,000 | D | A |
| 27 Feb, 2026 | Jared Oasheim | Common Stock | A | 61,000 | $0.00 | 98,447 | D | A |
| 27 Feb, 2026 | Paul Verrastro | Common Stock | A | 45,000 | $0.00 | 61,835 | D | A |
| 27 Feb, 2026 | Jared Oasheim | Common Stock | A | 61,000 | $0.00 | 98,447 | D | A |
| 27 Feb, 2026 | Brent Binkowski | Common Stock | A | 15,000 | $0.00 | 31,600 | D | A |
| 02 Mar, 2026 | Paul Verrastro | Common Stock | D | 1,284 | $7.90 | 60,551 | D | S |
| 02 Mar, 2026 | Robert Allen John | Common Stock | D | 3,964 | $7.90 | 86,036 | D | S |
| 02 Mar, 2026 | Jared Oasheim | Common Stock | D | 1,744 | $7.90 | 96,703 | D | S |
| 02 Mar, 2026 | Paul Verrastro | Common Stock | D | 1,284 | $7.90 | 60,551 | D | S |
| 27 Feb, 2026 | Brent Binkowski | Stock Option (right to buy) | A | 23,000 | $0.00 | 23,000 | D | A |
| 02 Mar, 2026 | Kevin Hykes | Common Stock | D | 7,763 | $7.90 | 284,237 | D | S |